
ARPA-H fast-tracks regenerative breakthroughs to transform osteoarthritis care
Extract:
Instead of just fixing worn-out joints with metal and plastic, NITRO (Novel Innovations for Tissue Regeneration in Osteoarthritis) teams are working to regrow real, living tissue, returning joints to their healthy state and eliminating evidence of disease.
In two years, NITRO teams hit aggressive preclinical milestones, regenerating both cartilage and bone in osteoarthritic animal models. They are now working to complete the IND-enabling studies required to secure FDA concurrence to begin first-in-human clinical trials next year.
Led by ARPA-H Program Manager Ross Uhrich, DMD, MBA, NITRO teams are reshaping regenerative medicine across all stages of the OA continuum with new approaches in the program’s three technical areas: targeted bone regeneration, targeted cartilage regeneration, and total knee implants composed of living human tissue.